Toggle light / dark theme

Boston Dynamics’ flagship Atlas humanoid robot picks up and places heavy automotive struts with ease in new footage.

In this latest demonstration of Atlas’ capabilities, the robot uses only its on-board sensors to detect the objects before using its grippers to pick up the struts from storage and insert them into a nearby flow cart. The footage also gives us a glimpse of the action from Atlas’ perspective.

Uh oh.

As The Independent reports, ChatGPT users have spent the last 24 hours or so flocking to social media to share screenshots and anecdotes of bizarre interactions with the OpenAI chatbot — which, well, appears to be losing its mind.

Screenshots show the AI’s responses to seemingly normal queries devolving into total gibberish, or simply generating way too much content. In one case highlighted by the Independent, a Redditor shared that the AI — when asked a question about coding, mind you — provided a garrulous and mostly illogical answer that included the statement: “let’s keep the line as if AI in the room.”

When spectacular cosmic events such as galaxy collisions occur, it sets off a reaction to form new stars, and possibly new planets that otherwise would not have formed. The gravitational pull that forces the collisions between these galaxies creates tidal tails—the long thin region of stars and interstellar gas.

The Hubble Space Telescope’s vision is so sharp that it can see clusters of newborn stars strung along these tidal tails. They form when knots of gas gravitationally collapse to create about 1 million newborn stars per cluster.

Specifically, NASA’s Hubble Space Telescope has homed in on 12 interacting galaxies that have long, tadpole-like tidal tails of gas, dust and a plethora of stars. Hubble’s exquisite sharpness and sensitivity to ultraviolet light have uncovered 425 clusters of newborn stars along these tails, looking like strings of holiday lights.

Artificial intelligence could bring about “biological conflict,” said former Google chief executive Eric Schmidt, who co-chaired the National Security Commission on Artificial Intelligence.

Schmidt spoke with defense reporters Sept. 12 as he helped release a new paper from his tech-oriented nonprofit think tank, the Special Competitive Studies Project. Schmidt launched the think tank with staff from the commission in order to continue the commission’s work.

AI’s applicability to biological warfare is “something which we don’t talk about very much,” Schmidt said, but it poses grave risks. “It’s going to be possible for bad actors to take the large databases of how biology works and use it to generate things which hurt human beings,” Schmidt said, calling that risk “a very near-term concern.”

According to a study published in the BMJ, a person’s chance of surviving cardiac arrest while receiving cardiopulmonary resuscitation (CPR) in a hospital is 22%, but that declines rapidly after only one minute to less than 1% after 39 minutes. The likelihood of leaving with no major brain damage is similar, declining from 15% after one minute of CPR to less than 1% after 32 minutes without a heartbeat.

Only around 25% of patients survive to hospital discharge after being admitted to the emergency department for cardiac arrest. This common catastrophic medical emergency with a high mortality rate is an important public health issue, affecting around 300,000 adults every year in America alone. Unfortunately, studies have shown that long resuscitation times are linked to lower odds of survival, but there are no specific recommendations on when to stop resuscitation.

This study was designed to measure the effects of CPR duration, using the largest cardiac dataset in the world, utilizing data from 348,996 adults with an average age of 67 years old who experienced an in-hospital cardiac arrest. CPR was defined as the interval between the start of compression and the first return of spontaneous circulation (ROSC) or the termination of resuscitation. The main measures of interest were survival to discharge and favorable function at discharge, defined as a brain performance score of 1 representing good cerebral performance, and 2 representing moderate cerebral disability on a 5-point scale.

CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.

Fabian Müller, M.D., from the Friedrich-Alexander University Erlangen-Nürnberg in Germany, and colleagues examined patients with severe systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, or systemic sclerosis (eight, three, and four patients, respectively) who received a single infusion of CD19 CAR T-cells after fludarabine and cyclophosphamide preconditioning.

Efficacy was assessed up to two years after CAR T-cell infusion, measured using the Definition of Remission in SLE (DORIS) criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index.